• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.16% Nasdaq Down0.08%

    Rigel Pharmaceuticals, Inc. (RIGL)

    3.05 Down 0.09(2.87%) Jul 2, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Rigel Pharmaceuticals, Inc.
    1180 Veterans Boulevard
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-624-1100
    Fax: 650-624-1101
    Website: http://www.rigel.com

    Index Membership:N/A
    Industry:Drugs - Generic
    Full Time Employees:127

    Business Summary 

    Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. It is developing fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura and Phase II clinical trials for IgA nephropathy; R348, a topical JAK/SYK inhibitor that is in Phase II clinical trials for the treatment of dry eye in ocular graft-versus-host disease; and two oncology product candidates in Phase I development. The company has a license agreement with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; a license agreement with BerGenBio AS for the development and commercialization of an oncology program; a collaboration agreement with Daiichi Sankyo to pursue research related to a specific target from a class of drug targets called ligases that control cancer cell proliferation through protein degradation; and a collaboration agreement with Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies. Rigel Pharmaceuticals, Inc. was founded in 1996 and is based in South San Francisco, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Rigel Pharmaceuticals, Inc.

    Corporate Governance 
    Rigel Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jun 1, 2015 is 4. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 3; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Raul R. Rodriguez , 54
    Chief Exec. Officer, Pres, Director and Member of Fin. Committee
    Dr. Donald G. Payan M.D., 66
    Co-Founder, Pres of Discovery & Research, Exec. VP and Director
    Mr. Ryan D. Maynard , 45
    Chief Financial Officer and Exec. VP
    Ms. Dolly A. Vance , 50
    Exec. VP of Corp. Affairs, Gen. Counsel and Corp. Sec.
    Dr. Elliott B. Grossbard M.D., 67
    Chief Medical Officer and Exec. VP
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders